4:04 pm Peregrine Pharma reports EPS in-line, beats on revs (PPH

4:04 pm Peregrine Pharma reports EPS in-line, beats on revs (PPHM) : Reports Q2 (Oct) loss of $0.05 per share, in-line with the Capital IQ Consensus Estimate consensus of ($0.05); revenues rose 21.3% year/year to $7.4 mln vs the $5.75 mln consensus.

请您先登陆,再发跟帖!